US5922857A
(en)
*
|
1992-09-28 |
1999-07-13 |
Chiron Corporation |
Methods and compositions for controlling translation of HCV proteins
|
US5472881A
(en)
*
|
1992-11-12 |
1995-12-05 |
University Of Utah Research Foundation |
Thiol labeling of DNA for attachment to gold surfaces
|
CN1136327A
(zh)
*
|
1993-09-28 |
1996-11-20 |
综合医院公司 |
用反义寡核苷酸调节神经生长并使β/A4淀粉样肽诱导的形态逆转
|
GB9602326D0
(en)
*
|
1996-02-06 |
1996-04-03 |
Cruachem Ltd |
Compounds
|
AU2542097A
(en)
*
|
1996-03-26 |
1997-10-17 |
Lynx Therapeutics, Inc. |
Oligonucleotide treatments and compositions for human melanoma
|
US5852168A
(en)
*
|
1996-04-30 |
1998-12-22 |
Regents Of The University Of Minesota |
Sulfurization of phosphorus-containing compounds
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US6172217B1
(en)
|
1996-12-27 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Method of synthesizing phosphorothioate oligonucleotides
|
US5902881A
(en)
*
|
1997-03-03 |
1999-05-11 |
Isis Pharmaceuticals, Inc. |
Reagent useful for synthesizing sulfurized oligonucleotide analogs
|
US5760209A
(en)
*
|
1997-03-03 |
1998-06-02 |
Isis Pharmaceuticals, Inc. |
Protecting group for synthesizing oligonucleotide analogs
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6114519A
(en)
*
|
1997-10-15 |
2000-09-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of sulfurized oligonucleotides
|
US6242591B1
(en)
*
|
1997-10-15 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of sulfurized 2'-substituted oligonucleotides
|
US7273933B1
(en)
|
1998-02-26 |
2007-09-25 |
Isis Pharmaceuticals, Inc. |
Methods for synthesis of oligonucleotides
|
US6069243A
(en)
*
|
1998-10-06 |
2000-05-30 |
Isis Pharmaceuticals, Inc. |
Process for oligonucleotide synthesis
|
US6184347B1
(en)
|
1998-11-19 |
2001-02-06 |
Agilent Technologies Inc. |
Minimization of blooming in high-density arrays by using reactive wash reagents
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
KR100856446B1
(ko)
|
1998-12-23 |
2008-09-04 |
화이자 인크. |
Ctla-4에 대한 인간 단일클론 항체
|
DE19906986C1
(de)
*
|
1999-02-19 |
2000-07-13 |
Rhein Chemie Rheinau Gmbh |
Verfahren zur Herstellung von Dithiophosphorsäurepolysulfid-Gemischen und deren Verwendung
|
JP2000325085A
(ja)
|
1999-05-21 |
2000-11-28 |
Masafumi Matsuo |
デュシェンヌ型筋ジストロフィー治療剤
|
ES2282133T3
(es)
|
1999-08-24 |
2007-10-16 |
Medarex, Inc. |
Anticuerpos frente a la ctla-4 humano y sus usos.
|
US7605238B2
(en)
*
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
US6653467B1
(en)
|
2000-04-26 |
2003-11-25 |
Jcr Pharmaceutical Co., Ltd. |
Medicament for treatment of Duchenne muscular dystrophy
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
PT1399483E
(pt)
|
2001-01-05 |
2010-07-20 |
Pfizer |
Anticorpos contra o receptor do factor i de crescimento tipo insulina
|
AU2002307554A1
(en)
*
|
2001-04-23 |
2002-11-05 |
Abgenix, Inc. |
Anti-alpha3(iv)nc1 monoclonal antibodies and animal model for human anti-glomerular basement membrane autoantibody disease
|
AU2002316384A1
(en)
*
|
2001-06-26 |
2003-03-03 |
Photomed Technologies, Inc. |
Multiple wavelength illuminator
|
PT2087908T
(pt)
|
2001-06-26 |
2018-07-16 |
Amgen Inc |
Anticorpos contra opgl
|
AR039067A1
(es)
*
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
US7255874B1
(en)
|
2001-12-21 |
2007-08-14 |
Closure Medical Corporation |
Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
|
US6578724B1
(en)
*
|
2001-12-29 |
2003-06-17 |
United States Can Company |
Connector for use in packaging aerosol containers
|
US7135174B2
(en)
*
|
2002-01-07 |
2006-11-14 |
Amgen Fremont, Inc. |
Antibodies directed to PDGFD and uses thereof
|
WO2003073233A2
(en)
*
|
2002-02-26 |
2003-09-04 |
Pharmacia Corporation |
Sequence detection system calculator
|
MXPA04009418A
(es)
|
2002-03-29 |
2005-06-08 |
Schering Corp |
Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
|
AU2003243139B2
(en)
|
2002-04-05 |
2007-06-21 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
JP2005529873A
(ja)
*
|
2002-04-12 |
2005-10-06 |
メダレックス インコーポレイテッド |
Ctla−4抗体を使用した治療の方法
|
NZ605429A
(en)
|
2002-09-06 |
2014-08-29 |
Amgen Inc |
Therapeutic human anti-il-1r1 monoclonal antibody
|
WO2004034988A2
(en)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
|
AU2003295387A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Parmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
ES2347239T3
(es)
|
2002-12-02 |
2010-10-27 |
Amgen Fremont Inc. |
Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
|
WO2004053105A2
(en)
*
|
2002-12-12 |
2004-06-24 |
Nanosphere, Inc. |
Direct snp detection with unamplified dna
|
JP2006517191A
(ja)
*
|
2002-12-30 |
2006-07-20 |
アムジエン・インコーポレーテツド |
共刺激因子を用いた併用療法
|
US20050130174A1
(en)
*
|
2003-02-27 |
2005-06-16 |
Nanosphere, Inc. |
Label-free gene expression profiling with universal nanoparticle probes in microarray assay format
|
EP1613750B1
(de)
|
2003-03-19 |
2015-10-14 |
Amgen Fremont Inc. |
Antikörper gegen das t-zellen-immunglobulindomäne- und mucindomäne-1 (tim-1) antigen und verwendungen davon
|
US20050250094A1
(en)
*
|
2003-05-30 |
2005-11-10 |
Nanosphere, Inc. |
Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes
|
CN104059147A
(zh)
|
2003-06-27 |
2014-09-24 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
RS53476B
(en)
|
2003-07-18 |
2014-12-31 |
Amgen Fremont Inc. |
Hepatocyte Growth Factor Binders
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
EP1659918B1
(de)
|
2003-08-08 |
2009-01-14 |
Amgen Fremont Inc. |
Antikörper gegen parath-hormon (pth) und ihre verwendungen
|
AR045563A1
(es)
*
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
SI2177537T1
(sl)
*
|
2004-01-09 |
2012-01-31 |
Pfizer |
Protitielesa proti MAdCAM
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
CA2560889A1
(en)
*
|
2004-03-23 |
2005-10-13 |
Sanjay D. Khare |
Monoclonal antibodies specific for human ox40l (cd 134l)
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
AU2005252662B2
(en)
*
|
2004-06-03 |
2011-08-18 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
EP1758999B1
(de)
|
2004-06-22 |
2011-03-09 |
The Board Of Trustees Of The University Of Illinois |
Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
EP2322217A3
(de)
*
|
2004-07-16 |
2011-09-28 |
Pfizer Products Inc. |
Kombinationsbehandlung für nicht-hämatologische bösartige Erkrankungen mit einem anti-IGF-1R-Antikörper
|
CA2572178A1
(en)
*
|
2004-07-26 |
2006-03-16 |
Nanosphere, Inc. |
Method for distinguishing methicillin resistant s. aureus from methicillin sensitive s. aureus in a mixed culture
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
EP1824886B1
(de)
|
2004-11-17 |
2010-12-22 |
Amgen Inc. |
Vollständige humane monoklonale antikörper gegen il-13
|
US20060166234A1
(en)
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
ATE504602T1
(de)
|
2004-12-20 |
2011-04-15 |
Amgen Fremont Inc |
Für humane matriptase spezifische bindungsproteine
|
RU2394839C2
(ru)
|
2004-12-21 |
2010-07-20 |
Астразенека Аб |
Антитела против ангиопоэтина-2 и их применение
|
EP1851245B1
(de)
|
2005-01-26 |
2012-10-10 |
Amgen Fremont Inc. |
Antikörper gegen interleukin-1-beta
|
AR062247A1
(es)
|
2005-03-08 |
2008-10-29 |
Pharmacia & Upjohn Co Llc |
Composiciones de anticuerpos anti-ctla-4
|
WO2007059082A1
(en)
|
2005-11-10 |
2007-05-24 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
JP2008539241A
(ja)
*
|
2005-04-25 |
2008-11-13 |
ファイザー インコーポレイティッド |
ミオスタチンに対する抗体
|
KR101193797B1
(ko)
|
2005-04-26 |
2012-10-23 |
화이자 인코포레이티드 |
P-카드헤린 항체
|
WO2006125124A2
(en)
*
|
2005-05-18 |
2006-11-23 |
Nanosphere, Inc. |
Substrate functionalization method for high sensitivity applications
|
WO2006138284A2
(en)
|
2005-06-15 |
2006-12-28 |
Callida Genomics, Inc. |
Nucleic acid analysis by random mixtures of non-overlapping fragments
|
WO2007002567A2
(en)
*
|
2005-06-23 |
2007-01-04 |
Nanosphere, Inc. |
Selective isolation and concentration of nucleic acids from complex samples
|
EP1907855A4
(de)
*
|
2005-07-12 |
2009-11-11 |
Univ Temple |
Genetische und epigenetische änderungen bei der diagnose und behandlung von krebs
|
SI1915398T1
(sl)
*
|
2005-07-18 |
2016-07-29 |
Amgen Inc. |
Humana nevtralizacijska protitelesa proti b7rp1
|
JP2009505106A
(ja)
*
|
2005-08-19 |
2009-02-05 |
ナノスフェアー インコーポレイテッド |
Dna及び抗体を含むハイブリッド基板を調製するための方法及びその使用
|
CA2621371C
(en)
*
|
2005-09-07 |
2018-05-15 |
Amgen Fremont Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
CN101325971A
(zh)
|
2005-12-07 |
2008-12-17 |
米德列斯公司 |
Ctla-4抗体剂量递增方案
|
CN105753983A
(zh)
|
2005-12-13 |
2016-07-13 |
阿斯利康(瑞典)有限公司 |
胰岛素样生长因子特异性结合蛋白及其用途
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
US20080085508A1
(en)
*
|
2006-05-11 |
2008-04-10 |
Nanosphere, Inc. |
Non-nucleic acid based biobarcode assay for detection of biological materials
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
PL2511301T3
(pl)
|
2006-08-04 |
2018-05-30 |
Medimmune Limited |
Ludzkie przeciwciała do ErbB2
|
AU2007299705B2
(en)
|
2006-09-22 |
2012-09-06 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
|
WO2008112269A2
(en)
|
2007-03-13 |
2008-09-18 |
Amgen Inc. |
K-ras mutations and anti-egfr antibody therapy
|
WO2008112274A2
(en)
|
2007-03-13 |
2008-09-18 |
Amgen Inc. |
K-ras and b-raf mutations and anti-egfr antibody therapy
|
US7845686B2
(en)
*
|
2007-12-17 |
2010-12-07 |
S & B Technical Products, Inc. |
Restrained pipe joining system for plastic pipe
|
CN104975020B
(zh)
|
2008-02-11 |
2020-01-17 |
菲奥医药公司 |
经修饰的RNAi多核苷酸及其用途
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
US8192738B2
(en)
|
2008-09-19 |
2012-06-05 |
Medimmune, Llc |
Targeted antibodies directed to DLL4
|
CA2746527A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
JP5645840B2
(ja)
|
2008-12-02 |
2014-12-24 |
株式会社Wave Life Sciences Japan |
リン原子修飾核酸の合成方法
|
AU2009331528A1
(en)
|
2008-12-23 |
2011-08-11 |
Astrazeneca Ab |
Targeted binding agents directed to alpha5beta1 and uses thereof
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
RU2605318C2
(ru)
|
2009-05-05 |
2016-12-20 |
Новиммун С.А. |
Анти-il-17f антитела и способы их применения
|
CN102596204B
(zh)
|
2009-07-06 |
2016-11-23 |
波涛生命科学有限公司 |
新的核酸前药及其使用方法
|
KR20120102674A
(ko)
|
2009-11-03 |
2012-09-18 |
유니버시티 오브 버지니아 페이턴트 파운데이션 |
중합체 분석물을 검출하는 다용도의 가시적인 방법
|
RS60033B1
(sr)
|
2009-11-24 |
2020-04-30 |
Medimmune Ltd |
Ciljano vezujući agensi usmereni na b7-h1
|
AU2011232365A1
(en)
|
2010-03-24 |
2012-10-25 |
Rxi Pharmaceuticals Corporation |
RNA interference in dermal and fibrotic indications
|
EP2550001B1
(de)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna-interferenz bei augenerkrankungen
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
US9273316B2
(en)
|
2010-05-21 |
2016-03-01 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
US20130203045A1
(en)
|
2010-05-26 |
2013-08-08 |
University Of Virginia Patent Foundation |
Method for detecting nucleic acids based on aggregate formation
|
CN103261222B
(zh)
|
2010-09-10 |
2017-07-28 |
医疗免疫有限公司 |
抗体衍生物
|
NZ607510A
(en)
|
2010-09-10 |
2014-10-31 |
Apexigen Inc |
Anti-il-1 beta antibodies and methods of use
|
EP2620428B1
(de)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetrische hilfsgruppe
|
JP6189215B2
(ja)
|
2010-11-01 |
2017-08-30 |
ペプチメッド, インコーポレイテッド |
細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物
|
WO2012096917A1
(en)
|
2011-01-10 |
2012-07-19 |
Novimmune S.A. |
Anti-tlr4 antibodies and methods of use thereof
|
MX342810B
(es)
|
2011-03-03 |
2016-10-13 |
Apexigen Inc |
Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
|
EP2683740B1
(de)
|
2011-03-10 |
2018-07-04 |
Omeros Corporation |
Erzeugung monoklonaler anti-fn14-antikörper durch ex-vivo beschleunigte antikörperentwicklung
|
WO2012149356A2
(en)
|
2011-04-29 |
2012-11-01 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
US8846042B2
(en)
|
2011-05-16 |
2014-09-30 |
Fabion Pharmaceuticals, Inc. |
Multi-specific FAB fusion proteins and methods of use
|
JP6128529B2
(ja)
|
2011-07-19 |
2017-05-17 |
ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. |
官能化核酸の合成のための方法
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
AU2012295394B2
(en)
|
2011-08-12 |
2016-04-14 |
Omeros Corporation |
Anti-FZD10 monoclonal antibodies and methods for their use
|
TWI571473B
(zh)
|
2011-11-02 |
2017-02-21 |
埃派斯進有限公司 |
抗kdr抗體及使用方法
|
AU2012335247A1
(en)
|
2011-11-08 |
2014-05-29 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-M-CSF antibodies
|
MX2014005957A
(es)
|
2011-11-16 |
2015-02-04 |
Amgen Inc |
Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico.
|
HUE13746964T2
(hu)
|
2012-02-06 |
2020-01-28 |
Inhibrx Inc |
CD47 antitestek és alkalmazási eljárásaik
|
US9677070B2
(en)
|
2012-03-15 |
2017-06-13 |
Omeros Corporation |
Composition and method for diversification of target sequences
|
SG11201406943XA
(en)
|
2012-04-27 |
2014-12-30 |
Cytomx Therapeutics Inc |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
AU2013287630B2
(en)
|
2012-07-13 |
2017-05-25 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant
|
PL2872485T3
(pl)
|
2012-07-13 |
2021-05-31 |
Wave Life Sciences Ltd. |
Asymetryczna grupa pomocnicza
|
WO2014012081A2
(en)
|
2012-07-13 |
2014-01-16 |
Ontorii, Inc. |
Chiral control
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
EP3925977A1
(de)
|
2012-10-30 |
2021-12-22 |
Apexigen, Inc. |
Anti-cd40-antikörper und verfahren zur verwendung
|
EP4137518A1
(de)
|
2013-02-06 |
2023-02-22 |
Inhibrx, Inc. |
Nicht-plättchen-depletierende und nicht-erythrozyten-depletierende cd47-antikörpern und verfahren zur verwendung davon
|
US9816989B2
(en)
|
2013-03-12 |
2017-11-14 |
Institute of Arthritis Research, LLC |
Immunologically active polypeptide
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
SG11201507273SA
(en)
|
2013-03-15 |
2015-10-29 |
Theranos Inc |
Nucleic acid amplification
|
US9517276B2
(en)
|
2013-06-04 |
2016-12-13 |
Cytomx Therapeutics, Inc. |
Compositions and methods for conjugating activatable antibodies
|
CA2918795A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
WO2015023851A1
(en)
|
2013-08-14 |
2015-02-19 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled proteins and methods of use thereof
|
EP3690048A1
(de)
|
2013-09-04 |
2020-08-05 |
Cold Spring Harbor Laboratory |
Reduzierung von fehlvermitteltem mrna-abbau
|
AU2014324884B2
(en)
|
2013-09-25 |
2020-03-26 |
Cytomx Therapeutics, Inc |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
US10934550B2
(en)
|
2013-12-02 |
2021-03-02 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer
|
WO2015082716A1
(en)
|
2013-12-06 |
2015-06-11 |
Novimmune S.A. |
Anti-tlr4 antibodies and methods of use thereof
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
EP3095460A4
(de)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
US10160969B2
(en)
|
2014-01-16 |
2018-12-25 |
Wave Life Sciences Ltd. |
Chiral design
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
DK3628328T3
(da)
|
2014-01-31 |
2022-12-05 |
Cytomx Therapeutics Inc |
Matriptase- og u-plasminogen-aktivatorsubstrater og andre spaltelige dele og fremgangsmåder til anvendelse deraf
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
EP3172235A2
(de)
|
2014-07-25 |
2017-05-31 |
Cytomx Therapeutics Inc. |
Anti-cd3-antikörper, aktivierbare anti-cd3-antikörper, multispezifische anti-cd3-antikörper, multispezifische aktivierbare anti-cd3-antikörper und verfahren zur verwendung davon
|
AU2015307186A1
(en)
|
2014-08-27 |
2017-04-13 |
Peptimed, Inc. |
Anti-tumor compositions and methods
|
WO2016037071A2
(en)
|
2014-09-05 |
2016-03-10 |
Rxi Pharmaceuticals Corporation |
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
AU2015327836B2
(en)
|
2014-10-03 |
2021-07-01 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
JP6585721B2
(ja)
|
2014-12-31 |
2019-10-02 |
ディヴェロップメント センター フォー バイオテクノロジー |
ヒト化α−エノラーゼ特異的抗体及びがん治療におけるその使用方法
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
MX2017011644A
(es)
|
2015-03-13 |
2017-12-04 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
|
BR112017023868A2
(pt)
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
|
SG10201913767VA
(en)
|
2015-05-04 |
2020-03-30 |
Cytomx Therapeutics Inc |
Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
|
EP4029880A1
(de)
|
2015-05-04 |
2022-07-20 |
CytomX Therapeutics, Inc. |
Aktivierbare anti-cd71-antikörper und verfahren zur verwendung davon
|
US11001845B2
(en)
|
2015-07-06 |
2021-05-11 |
Phio Pharmaceuticals Corp. |
Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
CA2991976A1
(en)
|
2015-07-13 |
2017-01-19 |
Cytomx Therapeutics, Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
KR102625783B1
(ko)
|
2015-09-25 |
2024-01-15 |
퀴아젠 사이언시스, 엘엘씨 |
라임병을 진단하기 위한 및 치료 후 라임병 스피로헤타 제거를 예측하기 위한 조성물 및 방법
|
JP6923517B2
(ja)
|
2015-10-09 |
2021-08-18 |
ユニバーシティ・オブ・サザンプトン |
遺伝子発現の調節及び脱制御されたタンパク質発現のスクリーニング
|
CN109563509B
(zh)
|
2015-10-19 |
2022-08-09 |
菲奥医药公司 |
靶向长非编码rna的减小尺寸的自递送核酸化合物
|
WO2017106382A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of central nervous system diseases
|
WO2017106364A2
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
JP2018538288A
(ja)
|
2015-12-14 |
2018-12-27 |
コールド スプリング ハーバー ラボラトリー |
アラジール症候群の処置のためのアンチセンスオリゴマー
|
WO2017106283A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of liver diseases
|
JP7049248B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
常染色体優性精神遅滞-5とドラベ症候群の処置のためのアンチセンスオリゴマー
|
WO2017123673A2
(en)
|
2016-01-11 |
2017-07-20 |
Inhibrx Lp |
Multivalent and multispecific ox40-binding fusion proteins
|
US10947317B2
(en)
|
2016-03-15 |
2021-03-16 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
US20190352426A1
(en)
|
2016-08-03 |
2019-11-21 |
Achaogen, Inc. |
Plazomicin antibodies and methods of use
|
BR112019008223A2
(pt)
|
2016-11-03 |
2019-07-16 |
Bristol-Myers Squibb Company |
anticorpos anti-ctla-4 ativáveis e usos dos mesmos
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
KR20190134654A
(ko)
|
2017-03-09 |
2019-12-04 |
싸이톰스 테라퓨틱스, 인크. |
Cd147 항체, 활성화가능한 cd147 항체, 그리고 이를 만들고, 이용하는 방법
|
KR20200005732A
(ko)
|
2017-04-11 |
2020-01-16 |
인히브릭스, 인크. |
제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법
|
US11168144B2
(en)
|
2017-06-01 |
2021-11-09 |
Cytomx Therapeutics, Inc. |
Activatable anti-PDL1 antibodies, and methods of use thereof
|
AU2018300189A1
(en)
|
2017-07-14 |
2020-01-30 |
Pfizer, Inc. |
Antibodies to MAdCAM
|
AU2018304711A1
(en)
|
2017-07-20 |
2020-01-16 |
Cytomx Therapeutics, Inc. |
Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
|
SG11202001590RA
(en)
|
2017-08-25 |
2020-03-30 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of conditions and diseases
|
US20190117789A1
(en)
|
2017-08-30 |
2019-04-25 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd166 antibodies and methods of use thereof
|
SG11202002384VA
(en)
|
2017-10-14 |
2020-04-29 |
Cytomx Therapeutics Inc |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
WO2019075417A1
(en)
|
2017-10-14 |
2019-04-18 |
Abbvie Inc. |
CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE
|
JP7317016B2
(ja)
|
2017-12-19 |
2023-07-28 |
スロゼン オペレーティング, インコーポレイテッド |
抗lrp5/6抗体及び使用方法
|
EP3762420A1
(de)
|
2018-03-09 |
2021-01-13 |
CytomX Therapeutics, Inc. |
Aktivierbare cd147-antikörper und verfahren zur herstellung und verwendung davon
|
BR112020020604A2
(pt)
|
2018-04-11 |
2021-01-12 |
Inhibrx, Inc. |
Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
|
EP3802604A1
(de)
|
2018-05-31 |
2021-04-14 |
Glyconex Inc. |
An biantennäre lewis-b und lewis-y antigene bindende, therapeutische antikörper
|
TW202019968A
(zh)
|
2018-08-13 |
2020-06-01 |
美商英伊布里克斯公司 |
Ox40結合多肽及其用途
|
BR112021008526A2
(pt)
|
2018-11-02 |
2021-08-10 |
Cytomx Therapeutics, Inc. |
anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
MX2021006429A
(es)
|
2018-12-06 |
2021-07-15 |
Cytomx Therapeutics Inc |
Sustratos escindibles con matriz de metaloproteasa, serina o cisteína escindible con proteasa y métodos de uso de estos.
|
JP2022523200A
(ja)
|
2019-02-26 |
2022-04-21 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法
|
CA3148591A1
(en)
|
2019-07-26 |
2021-02-04 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
JP2022548310A
(ja)
|
2019-09-23 |
2022-11-17 |
シートムエックス セラピューティクス,インコーポレイテッド |
抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法
|
CA3169827A1
(en)
|
2020-03-10 |
2021-09-16 |
Kunwar Shailubhai |
Compositions of il-6/il-6r antibodies and methods of use thereof
|
US20230312753A1
(en)
|
2020-05-04 |
2023-10-05 |
Immunorizon Ltd. |
Precursor tri-specific antibody constructs and methods of use thereof
|
AU2021270720A1
(en)
|
2020-05-11 |
2022-12-08 |
Stoke Therapeutics, Inc. |
OPA1 antisense oligomers for treatment of conditions and diseases
|
WO2022003530A1
(en)
|
2020-06-30 |
2022-01-06 |
Fondazione Toscana Life Sciences |
Neutralizing antibodies to sars coronavirus-2
|
IT202000015754A1
(it)
|
2020-06-30 |
2021-12-30 |
Fond Toscana Life Sciences |
Antibodies to coronavirus
|
WO2022020636A2
(en)
|
2020-07-24 |
2022-01-27 |
Amgen Inc. |
Immunogens derived from sars-cov2 spike protein
|
EP4256334A1
(de)
|
2020-12-04 |
2023-10-11 |
Qiagen Sciences LLC |
Zusammensetzungen und verfahren zur diagnose von sars-cov-2 (covid-19) und zur überwachung des sars-cov-2-spezifischen immunologischen gedächtnisses
|
IT202100003470A1
(it)
|
2021-02-16 |
2022-08-16 |
Fond Toscana Life Sciences |
Vaccines against sars-cov-2
|
WO2022221767A1
(en)
|
2021-04-16 |
2022-10-20 |
Tiziana Life Sciences Plc |
Subcutaneous administration of antibodies for the treatment of disease
|
WO2023094980A1
(en)
|
2021-11-23 |
2023-06-01 |
Fondazione Toscana Life Sciences |
Antibodies to coronavirus
|
WO2023117965A1
(en)
|
2021-12-20 |
2023-06-29 |
Freie Universität Berlin |
Methods and agents for increasing rbm3 expression
|
WO2024073404A1
(en)
|
2022-09-28 |
2024-04-04 |
Sarepta Therapeutics, Inc. |
Pompe disease mouse model generation, characterization and methods of use
|